<DOC>
	<DOCNO>NCT00207142</DOCNO>
	<brief_summary>The purpose study compare proportion subject HIV-1 RNA viral load &lt; 50 c/mL Week 48 Maintenance Phase among HIV-infected subject initial undetectable viral load follow Induction Phase ATV/RTV contain HAART regimen , switch ATV versus remain ATV/RTV , whilst continue previous NRTI backbone .</brief_summary>
	<brief_title>Induction-Maintenance With Atazanavir HIV Naïve Patients ( The INDUMA Study )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Treatment naive HIV1 infected subject ( &lt; 10 day treatment ARV ) . Subjects HIV1 RNA level ≥ 5000 c/mL screen . Subjects CD4 count ≥ 50 cells/mm3 . Men woman , age 18 year age old ( minimum age determine local regulatory legal requirement dictate ) . Both female childbearing potential male must utilize effective barrier contraception . Other contraception addition barrier method permit ; refer Investigator Brochure detail regard potential interaction ATV oral contraceptive WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 8 week study . WOCBP use prohibit contraceptive method . Caution warrant coadministration oral contraceptive ( ethinyl estradiol norethindrone ) see Investigator Brochure detail Women pregnant breastfeed Women positive pregnancy test enrollment prior study drug administration . Presence newly diagnose HIVrelated opportunistic infection medical condition require acute therapy time enrollment Primary HIV infection Medical History Concurrent Diseases Active alcohol substance use sufficient , investigator 's opinion , prevent adequate compliance study therapy increase risk develop pancreatitis chemical hepatitis Physical Laboratory Test Findings Screening laboratory value measure follow : Grade IV glucose , Grade IV electrolytes , Grade IV transaminase , Grade IV hematology . Hypersensitivity component formulation study drug Prior history take ARV 10 day Concomitant administration tenofovir ( TDF ) . Refer Section 6.4.1 detail prohibit therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>HIV-1 infect treatment naive patient</keyword>
</DOC>